The U.S. Food and Drug Administration (FDA) is hosting a hybrid in-person/virtual meeting on September 18, 2025, to meet the BsUFA III Commitment to review the progress of the pilot program’s aims, or demonstration projects, and solicit input on future priorities.
Similar Posts
Drug Trials Snapshots: LYNKUET
Drug Trials Snapshots: LYNKUETAspiration System Correction: Calyxo Updates Use Instructions for CVAC Aspiration Systems
This communication is part of the Communications Pilot to Enhance the Medical Device Recall ProgramOlympia Pharmaceuticals. Orlando, FL. 483 issued 08/08/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 08/08/2025
Short Title (70 char) Olympia Pharmaceuticals. Orlando, FL. 483 issued 08/08/2025
FEI Number 3009724085
Firm Name Olympia Pharmaceuticals
Record Type 483
State FL
Establishment Type Outsourcing FaciliWalgreen Company – 662158 – 12/19/2025
Failure to Register and ListRhino 69 Gummy may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Rhino 69 Gummy, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.Intravascular PICC Catheter Recall: Bard Removes PowerPICC Intravascular Catheters
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program